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i:10.1016/j.ejvs.2010.04.020The 3 published randomised trials comparing elective
endovascular versus open repair for abdominal aortic
aneurysms have been remarkably consistent in showing a 3-
fold 30-day operative survival benefit of endovascular
aneurysm repair (EVAR).1e3 These trials (EVAR 1, DREAM
and OVER) also have reported mid-term results, with
survival rates to between 2 and 4 years after random-
isation.3e5 Now for the first time long-term follow-up has
been reported for the EVAR trials6,7 and there are some
surprises, the sting in the tail.
The long-term follow-up of patients in clinical trials is of
vital importance,particularlywherethe life-expectancyof the
patients involvedmaybe10 yearsormore. Longevity in Europe
is increasing rapidly and many patients with aortic aneurysms
are likely to survive 10 years or more. The long-term follow-up
of patients also has been stressed in the recent IDEAL guide-
lines (InnovationeDevelopmenteEvaluationeAssessment and
Long-term follow-up).8
The EVAR 1 trial randomised patients with large aneu-
rysms (at least 5.5 cm in diameter, anatomically suitable for
EVAR) to either endovascular repair or open repair. Themean
age at entry into this trial was 74 years. After 8 years of
follow-up, 54% remained alive, exactly the same proportion
in those randomised to EVAR as in those randomised to open
repair: EVAR was not associated with a long-term survival
benefit.6 Therefore, other long-term outcomes are of great
importance to more than half of the patients and in partic-
ular, new endograft-related complications and re-interven-
tions were reported throughout the period of follow-up.ty for Vascular Surgery. PublisheThe reporting of new endograft-related complications,
in the EVAR group, was highest within the first 6 months of
aneurysm repair (48.7 new complications per 100-patient
years of follow-up), reducing to 9.0 new complications per
100-patient years of follow-up between 6 months and 4
years, and at 5.1 new complications per 100 person years
beyond 4 years: these rates are much higher than those
reported after open repair, although this is not without
complications. There was no trial proforma reporting of
complications such as incisional hernias which can occur
after open repair, but a sensitivity analysis was performed
in 2004 on a random selection of over 400 patients and very
few cases were identified. Although this under-reporting of
complications and re-interventions after open repair is
acknowledged there was similar under-reporting of
complications and re-interventions in the EVAR group since
day case data (eg diagnostic angiograms or minor re-inter-
ventions) were not collected. In addition to the complica-
tion and re-intervention rates, there is other evidence to
indicate that EVAR might not be as durable as open repair.
There were 25 secondary ruptures after EVAR, the majority
(72%) of which proved to be fatal but in contrast, there
were no secondary ruptures reported after open repair.
This was one of the surprises of the long-term results, with
consequences for all endovascular specialists.
Endograft ruptures appear to explain the erosion of the
statistically significant 3% aneurysm-related survival benefit
for EVAR versus open repair, observed during the first 4
years of follow-up,5 with weak evidence to suggest thatd by Elsevier Ltd. All rights reserved.
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EVAR group. After 6 years of follow-up the aneurysm-
related survival curves had converged, so that at 8 years,
the aneurysm-related survival was 93% in both groups.6 The
EVAR 1 trial used principally second and third generation
endografts, mainly Cook/Zenith (54%), Medtronic/Talent
(32%) and Gore/Excluder (6%), during the period
1999e2007. There are those who argue that the EVAR
durability problems observed in the EVAR 1 trial are based
on older versions of endografts and that the newer devices
have improved durability. However, there is no evidence to
support this statement and some suggest that the newer
devices, whilst easier to use, do not have improved dura-
bility: often endograft ruptures are late events. Moreover,
investigation of complication rates during the early and late
phases of the EVAR Trials provided no evidence of any
reduction in rates despite the introduction of newer graft
iterations.9 The licensing of any device for clinical use is
based on short-term (eg 1e2 years) safety and efficacy
data. These long-term results question the durability of
EVAR and for the moment there is no better evidence. The
EVAR Trials now have closed and further follow-up data will
not be forthcoming. Therefore the careful long-term
follow-up and reporting of patients undergoing EVAR in
2010 and onwards is essential, probably through well-
organised registries such as those in Sweden and
Finland10,11 with some justification for mandatory partici-
pation. It also is possible that the uncertainty about the
long-term durability of EVAR might swing patient prefer-
ences away from endovascular repair: patient preference
now should now be a key feature in determining the choice
of technique for aneurysm repair.
The EVAR 2 trial was unique, the only trial to test the
indication for which EVAR was first introduced: the repair of
aneurysms in the very frail and those not considered
candidates for open repair. After 4 years of follow-up,
there was no convincing evidence that EVAR improved
either all-cause survival or aneurysm-related survival and
the 4 year survival was only 36%.12 Now after 8 years of
follow-up EVAR is associated with much improved aneu-
rysm-related survival (86% at 6 years versus 64% for no
intervention, adjusted HR 0.53; 95% CI 0.32e0.92) although
no clear difference in all-cause survival was observed (30%
at 6 years versus 26%, HR 0.99; 95% CI 0.78e1.27).7 The
ability of EVAR to reduce aneurysm rupture (and aneurysm-
related mortality) but not to improve survival is the sting in
the tail for EVAR 2. However after 8 years less than 20% of
the patients remained alive, so that the long-term
outcomes for these patients might carry less weight than
for those enrolled in EVAR trial 1.
Just as the long-term results of EVAR 1 are being chal-
lenged by those who think that new endografts will perform
better, the results of the EVAR 2 trial are challenged by
those who argue that EVAR was not being done quickly
enough in these frail, unfit patients and also criticise the
number of patients in the no intervention group who
eventually had aneurysm repair (31%). However, in the
main these were patients of very limited life-expectancy
who needed careful medical therapy to manage them
through even the minimally invasive procedure of EVAR.
Other patients who were not considered eligible for EVAR 1
at baseline may have improved eg. through bettermanagement of unstable angina. In addition, equipoise is
more difficult to maintain as the aneurysm enlarges and the
risk of rupture is heightened. No other trial has attempted
to assess the value of EVAR in such frail patients. The
pragmatic design of the EVAR 2 trial was correct and has
permitted the accumulation of much important evidence.
So where are we now? Clearly we await the results of
updated long-term cost-effectiveness modelling for both
trials, which currently is underway and should be
completed by the end of 2010. This modelling will guide the
future recommendations for the use of EVAR in tax-funded
health economies and will be read closely by those in
insurance funded economies. For the majority of patients
EVAR still provides short-term but not long-term benefits
but it is clear that long-term surveillance cannot be
dispensed with, although this may not need to be through
regular CT scan. For the very frail patient with multiple co-
morbidities, if life-expectancy is adequate EVAR after
appropriate medical optimisation may bring some benefits:
if life-expectancy is short EVAR is unlikely to bring any
benefits. Future work modelling the extent of any benefit in
subgroups may help clarify this issue.
It was the clinical decisionmaking skills of the participating
investigators that allowed the careful discrimination of
patients as being suitable for eitherEVARtrial 1 or EVARtrial 2,
withhelp fromthetrialprotocol“traffic light system”6,7 online
supplements. The late results of the EVAR trials indicate that
clinical decision making skills remain of crucial importance in
the management of patients with large aneurysms.References
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